読書リサーチレーダー投資フレームワーク
ログイン / 新規登録
← 読解に戻る
ニューストピック · 英伟达生物计算拓展クイックテイク1 分で読めるDisconfirmAI 編集部

NVIDIA video: Lila Sciences' AI agents and automated labs for drug discovery

NVIDIA's official channel released a video detailing how biotech firm Lila Sciences uses NVIDIA Nemotron and Agent Toolkit to build experimental plans, filters candidates via millions of virtual experiments using BioNeMo, and validates them with robotic instruments in its AI Science Factory. The resource illustrates the specific workflow connecting AI agents to autonomous labs.

2026-10-21 22:00 GMT+8

NVIDIA published a video on its official YouTube channel on October 21, 2026, introducing how biotechnology company Lila Sciences combines artificial intelligence agents with automated laboratories to accelerate drug discovery. This resource offers reference value for professional readers interested in the concrete implementation of "AI for Science."

According to the video description, Lila Sciences is exploring a therapy designed to help a patient’s own immune cells fight B-cell lymphoma. The workflow consists of two main stages: first, building an experimental plan using NVIDIA Nemotron and NVIDIA Agent Toolkit, while models built with NVIDIA BioNeMo run millions of virtual experiments to identify promising candidate molecules. Subsequently, these candidates are sent to Lila’s "AI Science Factory," where robotic instruments manufacture and test them.

The core of this case lies in the data feedback loop: results from physical lab tests return to inform the next round of designs and experiments. Although this entry is based solely on the publisher's descriptive information and does not include full interview dialogue or independent reproduction data, it clearly outlines the typical architecture of current AI-driven drug development involving "computational screening + automated wet-lab validation."

ソース

ログイン / 新規登録
読書リサーチレーダー投資フレームワーク
youtube.com
↗
トピック

英伟达生物计算拓展

英伟达正加速渗透生命科学领域,试图通过开源模型与硬件集群构建AI制药基础设施。2026年10月,英伟达联合华盛顿大学医学蛋白质设计研究所(IPD)发布RFD4-Proteina开源模型,宣称其计算设计成功率优于基线,并已与亚马逊、OpenA…

4 ステップ3 件更新日 2026-10-22 16:59

経緯

  1. 2026-03-16瑞士药企罗氏宣布与英伟达扩大合作,新增2,176个Blackwell GPU,旨在打造业界最大的混合云AI工厂以加速药物开发。fiercebiotech.com ↗
  2. 2026-10-21英伟达在GTC柏林发布RFD4-Proteina开源蛋白质设计模型,并宣布与西门子医疗合作开发下一代自适应放疗系统。nvidianews.nvidia.com ↗
  3. 2026-10-22英伟达官方频道发布视频,展示Lila Sciences如何利用NVIDIA Nemotron和Agent Toolkit构建自主实验室工作流。youtube.com ↗

未解決の問題

  • RFD4-Proteina在真实世界药物发现中的临床转化率是否显著高于传统方法?
  • 英伟达与金斯瑞等合作伙伴的生态模式能否有效解决AI设计与湿实验验证之间的脱节问题?
  • 随着AI深入医疗核心环节,监管机构对算法辅助诊断和治疗规划的审批标准将如何演变?

このスレッド内の他の記事

  • NVIDIA and IPD: Showcasing How AI Moves from Computer Models to Lab Protein Design2026-10-22
  • NVIDIA Releases RFD4-Proteina Open Model for Protein Design, Claims Higher Success Rates Than Baselines2026-10-21
トピック全文を読む →
リサーチを続ける →